

# **MEDI-CAPS LIMITED**

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231

Pithampur - 454775, Dist. Dhar

Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- [investors@medicaps.com](mailto:investors@medicaps.com)

Web site:- [www.medicaps.com](http://www.medicaps.com)

MCL/SE/2020-2021

DATE: 5<sup>th</sup> Feb., 2021

Online filing at: [www.listing.bseindia.com](http://www.listing.bseindia.com)

To,  
The General Manager  
DCS-CRD  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street Fort, Mumbai – 400001(M.H.)

**BSE Scrip Code: 523144**

**Subject: Submission of the Standalone and Consolidated Unaudited Financial Results for the Quarter as well as Nine months ended on 31<sup>st</sup> December, 2020 as per Regulation 33(3) of SEBI (LODR) Regulations, 2015.**

Dear Sir/Madam,

This is in Continuation of our letter no. MCL/BM/SE/2020-2021 dated 30<sup>th</sup> January, 2021 regarding submission of Standalone as well as Consolidated Unaudited Quarterly Financial Results for the Quarter as well as nine months ended on 31<sup>st</sup> December, 2020.

We are pleased to inform that, the Audit Committee and Board of Directors at their meetings held on 5<sup>th</sup> Feb., 2021 has considered and approved the following business:

- Unaudited Standalone and Consolidated Financial Results for the Quarter as well as nine months ended 31<sup>st</sup> December, 2020; and
- Limited Review Report by the Auditors for the Unaudited Standalone and Consolidated Financial Results for the Quarter ended 31<sup>st</sup> December, 2020.

We are also in process of filing the aforesaid financial results in the XBRL format within the stipulated time and the same shall be hosted on the Website of the Company.

The Meeting of the Board of Directors commenced at 3:00 P.M. and concluded at 4:00 P.M.


The above results will be published in Hindi (vernacular) and widely circulated English Newspaper.

You are requested to please take on record the aforesaid Unaudited Standalone and Consolidated Financial Results along with Limited review Report for your records and reference.

Thanking You,  
Yours Faithfully,

For, **MEDI-CAPS LIMITED**

  
**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321



Encl.: 1)-Unaudited Standalone and Consolidated Financial Results along with limited review report;

Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,  
Opposite VCO Bank Indore (M.P.) 452001  
Contact No: 0731-4028148

# RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com, cpawka@gmail.com

## LIMITED REVIEW REPORT ON UNAUDITED STANDALONE QUARTERLY FINANCIAL RESULTS OF MEDI-CAPS LIMITED

To,  
THE BOARD OF DIRECTORS OF  
MEDI-CAPS LIMITED

1. We have reviewed the accompanying Unaudited Standalone Financial Results of **MEDI-CAPS LIMITED** ("the Company"), for the Quarter ended December 31, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim financial reporting "IND AS 34" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

2. We conducted our review of the statement in accordance with the Standard on review engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
4. On 21st Nov., 2019, the company announced to permanently discontinue Company's operations related to production/manufacturing of Hard Gelatin Capsule Shell in the plant situated at Mhow - Neemuch Road, Sector 1, Pithampur - 454775, Distt. Dhar. The discontinuation is consistent with the Company's long-term strategy to focus its activities in the areas of Real Estate Business and to divest unrelated activities. Accordingly, Loss for the quarter ended December 31, 2020 from discontinuing operation of Rs 8.91lakhs.
5. Our conclusion on the Statement is not modified in respect of the above matter


Place: Indore

Date: 05/02/2021

UDIN: 21429040AAAABI1801

For: Rawka & Associates  
(Chartered Accountants)



  
Venus Rawka  
(Partner)  
M. No. 429040  
FRN: 021606C

# MEDI-CAPS LIMITED


CIN: L70100MP1983PLC002231

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DIST. DHAR (M.P.),

Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31<sup>ST</sup> DECEMBER 2020

(Amount in Rupees except EPS)							
Sr. No.	Particulars	Quarter Ended			Nine Month Ended		Previous Year ended on 31.03.2020
		3 Months ended on 31.12.2020	Previous 3 Months ended on 30.09.2020	Corresponding 3 Months ended on 31.12.2019	Year to date figures for current period ended on 31.12.2020	Year to date figures for previous period ended on 31.12.2019	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	<b>Revenue from operations</b>						
	(a) Net sales	0.00	0.00	185.62	0.00	1017.83	1090.85
	(b) Other operating income	0.00	0.00	1.44	0.00	39.25	56.59
<b>I</b>	<b>Total Revenue from operation</b>	<b>0.00</b>	<b>0.00</b>	<b>187.06</b>	<b>0.00</b>	<b>1057.08</b>	<b>1147.44</b>
<b>II</b>	<b>Other Income</b>	0.00	0.00	35.46	0.00	38.77	55.15
<b>III</b>	<b>Total income (I+II)</b>	<b>0.00</b>	<b>0.00</b>	<b>222.52</b>	<b>0.00</b>	<b>1095.84</b>	<b>1202.59</b>
<b>IV</b>	<b>Expenses</b>						
	a) Cost of material consumed	0.00	0.00	101.71	0.00	522.03	541.03
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	222.63	0.00	432.30	452.75
	d) Employee benefits expense	0.00	0.00	309.85	0.00	535.84	588.21
	e) Finance costs	0.00	0.00	0.20	0.00	0.70	0.86
	f) Power Cost	0.00	0.00	38.42	0.00	194.33	194.67
	g) Depreciation and amortization	0.00	0.00	10.19	0.00	27.17	35.54



# MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DIST. DHAR (M.P.),  
Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31<sup>ST</sup> DECEMBER 2020

	expense						
	h) Other expenses	0.00	0.00	48.24	0.00	202.66	221.36
	<b>Total Expenses (IV)</b>	<b>0.00</b>	<b>0.00</b>	<b>731.24</b>	<b>0.00</b>	<b>1915.03</b>	<b>2034.42</b>
<b>V</b>	<b>Profit / (Loss) before exceptional item &amp; tax (III-IV)</b>	<b>0.00</b>	<b>0.00</b>	<b>-508.73</b>	<b>0.00</b>	<b>-819.19</b>	<b>-831.83</b>
<b>VI</b>	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
<b>VII</b>	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>0.00</b>	<b>0.00</b>	<b>-508.73</b>	<b>0.00</b>	<b>-819.19</b>	<b>-831.83</b>
<b>VIII</b>	Tax expense						
	a) Current Tax	0.00	0.00	0.00	0.00	2.00	0.00
	b) Deferred Tax	0.00	0.00	0.00	0.00	1.64	0.84
	<b>Total Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>3.64</b>	<b>0.84</b>
<b>IX</b>	Profit (Loss) for the period from continuing operations (VII-VIII)	<b>0.00</b>	<b>0.00</b>	<b>-508.73</b>	<b>0.00</b>	<b>-822.83</b>	<b>-832.67</b>
<b>X</b>	Profit/(loss) from discontinued operations	-8.91	-5.14	0.00	-41.50	0.00	0.00
<b>XI</b>	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
<b>XII</b>	Profit/(loss) from Discontinued operations (after tax) (X-XI)	<b>-8.91</b>	<b>-5.14</b>	<b>0.00</b>	<b>-41.50</b>	<b>0.00</b>	<b>0.00</b>
<b>XIII</b>	Profit/(loss) for the period (IX+XII)	<b>-8.91</b>	<b>-5.14</b>	<b>-508.73</b>	<b>-41.50</b>	<b>-822.83</b>	<b>-832.67</b>
<b>XIV</b>	Other comprehensive income						
	(a)(i) Items that will not be reclassified to profit & loss	48.13	24.29	-18.10	105.59	104.99	66.41
	(ii) Income tax relating to items that will not to be reclassified to Profit & Loss	0.00	0.00	0.00	0.00	0.00	0.00



# MEDI-CAPS LIMITED


CIN: L70100MP1983PLC002231

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-I, PITHAMPUR-454775. DIST. DHAR (M.P.),

Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31<sup>ST</sup> DECEMBER 2020

	(b)(i) Items that will be reclassified to profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to Profit & Loss	0.00	0.00	0.00	0.00	0.00	0.00
<b>XV</b>	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	<b>39.22</b>	<b>19.15</b>	<b>-526.83</b>	<b>64.09</b>	<b>-717.84</b>	<b>-766.26</b>
<b>XVI</b>	Paid-up equity share capital of the company (Face value Rs.10/- Per Share)	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
<b>XVII</b>	Reserves excluding revaluation reserves	0.00	0	0	0	0	4737.52
<b>XVIII</b>	Earnings per equity share (for continuing operation)						
	a) Basic	0.39	0.19	-4.22	0.85	-5.76	-6.14
	a) Diluted	0.39	0.19	-4.22	0.85	-5.76	-6.14
<b>XIX</b>	Earnings per equity share (for discontinued operation)						
	a) Basic	-0.07	-0.04	0.00	-0.33	0.00	0.00
	a) Diluted	-0.07	-0.04	0.00	-0.33	0.00	0.00
<b>XX</b>	Earnings per equity share (for discontinued and continuing operation)						



# MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231


REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DIST. DHAR (M.P.),  
Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)


## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31<sup>ST</sup> DECEMBER 2020

a) Basic	0.32	0.15	-4.22	0.52	-5.76	-6.14
a) Diluted	0.32	0.15	-4.22	0.52	-5.76	-6.14

Date: 05.02.2021  
Place: INDORE

For, MEDI-CAPS LIMITED

  
ALOK K. GARG  
MANAGING DIRECTOR  
DIN: 00274321



# RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

412, Arcade Silver 56, 1, New Palasia, Indore - 1


☎ Off. : 2541132, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com, . cpawka@gmail.com

## **Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

### **TO THE BOARD OF DIRECTORS OF Medi-Caps Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Medi-Caps Limited** and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiary for the quarter ended 31/12/2020 and for the period from 01/10/2020 to 31/12/2020, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31/12/2020 and the corresponding period from 01/10/2020 to 31/12/2020, as reported in these financial results have been approved by the Parent's Board of Directors.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.


4. The Statement includes the results of its subsidiary Medgel Private Limited.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consolidated review report of its subsidiary, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Our conclusion is not modified in respect of this matter.
7. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of Medgel Private Limited (subsidiary) which have not been reviewed/audited by their auditors, whose interim consolidated financial statements/ financial information/ financial results reflect total revenue of Rs1827.34 Lakhs, total net profit/(loss) after tax of Rs.334.15 Lakhs and total comprehensive income of Rs. 96.30 Lakhs for the quarter ended 31/12/2020, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Place: Indore

Date: 05/02/2021

UDIN: 21429040AAAABH4494

**For: Rawka & Associates**  
Chartered Accountants



**Venus Rawka**  
(Partner)

M.No. 429040

FRN: 021606C



# MEDI-CAPS LIMITED


CIN: L70100MP1983PLC002231

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DIST. DHAR (M.P.),

Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31<sup>ST</sup> DECEMBER 2020

(Amount in Rs. except EPS)							
Sr. No.	Particulars	Quarter ended			Nine Month Ended		Previous Year ended on 31.03.2020
		3 Months ended on 31.12.2020	Previous 3 Months ended on 30.09.2020	Corresponding 3 Months ended on 31.12.2019	Year to date figures for current period ended on 31.12.2020	Year to date figures for previous period ended on 31.12.2019	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	<b>Revenue from operations</b>						
	(a) Net sales	1752.73	1476.59	852.33	4432.14	3714.30	4305.20
	(b) Other operating income	63.46	7.00	1.44	87.47	39.25	227.49
<b>I</b>	<b>Total Revenue from operation</b>	<b>1816.19</b>	<b>1483.59</b>	<b>853.77</b>	<b>4519.61</b>	<b>3753.54</b>	<b>4532.70</b>
<b>II</b>	<b>Other Income</b>	11.15	3.62	96.44	42.97	-10.61	59.53
<b>III</b>	<b>Total income (I+II)</b>	<b>1827.34</b>	<b>1487.20</b>	<b>950.21</b>	<b>4562.58</b>	<b>3742.94</b>	<b>4592.24</b>
<b>IV</b>	<b>Expenses</b>						
	a) Cost of material consumed	938.80	833.70	414.29	2322.20	1928.13	2232.80
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	89.01	-141.42	200.54	-29.15	395.23	449.65
	d) Employee benefits expense	178.40	171.49	430.04	482.76	891.01	1103.77
	e) Finance costs	0.00	0.00	0.88	0.00	1.51	1.69
	f) Power Cost	50.12	66.18	76.27	167.27	318.98	374.76
	g) Depreciation and amortization	37.31	37.31	47.73	111.93	138.25	183.01



# MEDI-CAPS LIMITED


CIN: L70100MP1983PLC002231

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DIST. DHAR (M.P.),

Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31<sup>ST</sup> DECEMBER 2020

	expense						
	h) Other expenses	190.65	207.58	112.10	613.98	559.42	830.90
	<b>Total Expenses (IV)</b>	<b>1484.29</b>	<b>1174.83</b>	<b>1281.84</b>	<b>3668.99</b>	<b>4232.53</b>	<b>5176.58</b>
V	<b>Profit / (Loss) before exceptional item &amp; tax (III-IV)</b>	<b>343.05</b>	<b>312.37</b>	<b>-331.63</b>	<b>893.59</b>	<b>-489.60</b>	<b>-584.34</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>343.05</b>	<b>312.37</b>	<b>-331.63</b>	<b>893.59</b>	<b>-489.60</b>	<b>-584.35</b>
VIII	Tax expense						
	a) Current Tax	0.00	0.00	0.00	0.00	2.00	0.00
	b) Deferred Tax	0.00	0.00	0.00	0.00	1.64	0.84
	<b>Total Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>3.64</b>	<b>0.84</b>
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	<b>343.05</b>	<b>312.38</b>	<b>-331.63</b>	<b>893.59</b>	<b>-493.24</b>	<b>-585.19</b>
X	Profit/(loss) from discontinued operations	-8.91	-5.14	0.00	-41.50	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-8.91	-5.14	0.00	-41.50	0.00	0.00
XIII	<b>Profit/(loss) for the period (IX+XII)</b>	<b>334.14</b>	<b>307.24</b>	<b>-331.63</b>	<b>852.09</b>	<b>-493.24</b>	<b>-585.19</b>
XIV	Other comprehensive income						
	(a) (i) items that will not be reclassified to profit & loss	96.30	52.56	3.27	221.96	138.32	120.30
	(ii) Income tax relating to items that will not to be reclassified to profit & loss	0.00	0.00	0.00	0.00	0.00	0.00



# MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DIST. DHAR (M.P.),

Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31<sup>ST</sup> DECEMBER 2020

	(b) (i) items that will be reclassified to profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
<b>XV</b>	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	<b>430.44</b>	<b>359.80</b>	<b>-328.36</b>	<b>1074.05</b>	<b>-354.91</b>	<b>-464.89</b>
<b>XVI</b>	Paid-up equity share capital of the company (Face value Rs.10/- Per Share)	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
<b>XVII</b>	Reserves excluding revaluation reserves	0.00	0.00	0.00	0.00	0.00	7848.45
<b>XVIII</b>	Earnings per equity share (for continuing operation)						
	a) Basic	3.52	2.93	-2.63	8.95	-2.85	-3.73
	a) Diluted	3.52	2.93	-2.63	8.95	-2.85	-3.73
<b>XIX</b>	Earnings per equity share (for discontinued operation)						
	a) Basic	-0.07	-0.04	0.00	-0.33	0.00	0.00
	a) Diluted	-0.07	-0.04	0.00	-0.33	0.00	0.00
<b>XX</b>	Earnings per equity share (for discontinued and continuing operation)						



# MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DIST. DHAR (M.P.),


Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31<sup>ST</sup> DECEMBER 2020


a) Basic	3.45	2.89	-2.63	8.62	-2.85	-3.73
a) Diluted	3.45	2.89	-2.63	8.62	-2.85	-3.73

Date: 05.02.2021  
Place: INDORE

For, MEDI-CAPS LIMITED



**ALOK K. GARG**  
MANAGING DIRECTOR  
DIN: 00274321



# MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231


REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DIST. DHAR (M.P.),

Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)

## SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR QUARTER ENDED 31<sup>ST</sup> DECEMBER, 2020

( Amount in Lakhs)

S.N.	Particulars	Quarter Ended		Year to Date	Year Ended
		31.12.2020	30.09.2020	Figure, Current	31.03.2020
		Unaudited	Unaudited	Period ended	Audited
1	<b>Segment Revenue</b>				
	Pharma Division	1,752.73	1,476.59	4,432.14	4,575.48
	Real Estate Division	0.00	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00
	<b>Gross Turnover</b>	<b>1,752.73</b>	<b>1,476.59</b>	<b>4,432.14</b>	<b>4,575.48</b>
2	<b>Segment Results</b>				
	Pharma Division	343.04	312.38	893.59	(582.66)
	Real Estate Division	0.00	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00
	<b>Total Segment Profit Before Interest &amp; Tax</b>	<b>343.04</b>	<b>312.38</b>	<b>893.59</b>	<b>(582.66)</b>
	Interest Income	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	0.00	0.00	1.69
	Other Unallocable Income net of Expenditure	0.00	0.00	0.00	0.00
	<b>Profit Before Tax</b>	<b>343.04</b>	<b>312.38</b>	<b>893.59</b>	<b>(584.35)</b>
	Provision for current tax	0.00	0.00	0.00	0.00
	Item Related Earlier Year	0.00	0.00	0.00	0.00
	<b>Profit After Tax</b>	<b>343.04</b>	<b>312.38</b>	<b>893.59</b>	<b>(584.35)</b>



# MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DIST. DHAR (M.P.),


Tel: 07292-256205, Website: [www.medicaps.com](http://www.medicaps.com) Email: [investors@medicaps.com](mailto:investors@medicaps.com)


3	<b>Capital Employed</b>				
	<b>Segment Assets (A)</b>				
	Pharma Division	10,936.33	10,666.54	10,936.33	9,521.06
	Real Estate Division	100.00	25.00	100.00	0.00
	Other	0.00	0.00	0.00	0.00
	<b>Total (A)</b>	<b>11,036.33</b>	<b>10,691.54</b>	<b>11,036.33</b>	<b>9,521.06</b>
	<b>Segment Liabilities (B)</b>				
	Pharma Division	766.83	927.88	766.83	425.61
	Real Estate Division	100.00	25.00	100.00	0.00
	Other	0.00	0.00	0.00	0.00
	<b>Total (B)</b>	<b>866.83</b>	<b>952.88</b>	<b>866.83</b>	<b>425.61</b>
4	<b>Capital Employed (Segment Assets-Segment Liabilities)</b>				
	Pharma Division	10,169.50	9,738.66	10,169.50	9,095.45
	Real Estate Division	0.00	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>	<b>10,169.50</b>	<b>9,738.66</b>	<b>10,169.50</b>	<b>9,095.45</b>

\* It may please be noted that there was no segment reporting in the corresponding quarter of the previous year i.e. December 31, 2019 and hence not reported.

Date: 05.02.2021  
Place: Indore

For, MEDI-CAPS LIMITED

  
ALOK K. GARG  
MANAGING DIRECTOR  
DIN: 00274321




**NOTES:**

1. The above standalone and consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 05<sup>th</sup> Feb., 2021. The Unaudited Standalone and Consolidated Financial Results for the quarter and nine month ended December 31<sup>st</sup>, 2020 have been subjected to limited review by the Statutory Auditors, who have expressed an Unmodified Opinion.
2. The financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.
3. The above consolidated financial result for the quarter ended 31<sup>st</sup> December, 2020 includes the result of wholly owned subsidiary company Medgel Private Limited.
4. Previous period/year figures have been regrouped wherever found necessary, to conform to current period / year classification.
5. There was no major impact of COVID-19, as company had already discontinued the manufacturing activities since November, 2019. However due to COVID-19 various approval from statutory authorities for real estate project is delayed.
6. As per Ind AS 108 Operating Segments, if a single financial report contains both consolidated financial statements and the standalone financial statements of the Parent Company. Segment information may be presented on the basis of the consolidated financial statements. After discontinuation of pharma business, the company has entered into Real Estate Business for which the company has applied for various licenses and approval from various government departments which are pending for approval. Thus disclosure required by regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 on segment information is given in consolidated financial results from this quarter.
7. The aforesaid Un-audited financial results will be uploaded on the Company's website [www.medicaps.com](http://www.medicaps.com) and will also available on the website of the Stock Exchange i.e. [www.bseindia.com](http://www.bseindia.com) for the benefit of shareholders and investors.


**8. Description of Income & Expenditure of Discontinue Operation:**

Particulars	3 Month Ended 31.12.2020	3 Month Ended 30.09.2020	9 Month Ended 31.12.2020
I Income from operations			
II Other Income	41.04	34.43	86.11
<b>III Total income (I+II)</b>	<b>41.04</b>	<b>34.43</b>	<b>86.11</b>
IV Expenses			



a) Changes in Inventories of finished goods, & work in progress	27.35	19.92	47.8
b) Employee benefits expense	6.05	1.95	12.63
c) Finance Cost	0.05	0.10	0.28
d) Depreciation expense	9.06	9.05	27.17
e) Other expenses	7.45	8.54	39.73
<b>Total Expenses (IV)</b>	<b>49.95</b>	<b>39.56</b>	<b>127.61</b>
<b>Net Loss From Discontinue Operation</b>	<b>-8.91</b>	<b>-5.13</b>	<b>-41.50</b>

Place : INDORE  
Date : 05/02/2021



FOR MEDICAPS LIMITED

*[Handwritten Signature]*

**ALOK K GARG**  
**MANAGING DIRECTOR**  
**DIN: 00274321**